文献速递浆细胞疾病

接受强化抗CD38抗体治疗的超高危多发性骨髓瘤患者对COVID-19加强疫苗接种的免疫应答:来自英国骨髓瘤协会(MUK)九项OPTIMUM试验的结果

Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.
PubMed 文献 · Br J Haematol · 2023-03-09

该研究在MUK九项试验中纵向监测接受风险适应强化抗CD38联合治疗的超高危多发性骨髓瘤患者的抗SARS-CoV-2抗体。尽管持续强化治疗,所有患者均实现血清转化,但所需疫苗接种次数多于健康个体,凸显加强接种的重要性。在当前关注变异株中观察到高抗体交叉反应,多剂加强疫苗可提供有效保护。

要点

  • 所有接受强化抗CD38治疗的患者均实现血清转化,但需更多疫苗剂次。
  • 加强接种对高危多发性骨髓瘤患者至关重要。
  • 当前关注变异株中观察到高抗体交叉反应。

核心结论

  • 多剂加强疫苗可提供有效COVID-19保护,即使在高危多发性骨髓瘤患者接受强化抗CD38治疗时也是如此。

研究设计与样本

  • 研究为MUK九项试验的一部分,纵向检测接受风险适应强化抗CD38联合治疗的超高危多发性骨髓瘤患者的抗SARS-CoV-2抗体。

主要发现

  • 尽管持续强化治疗,所有患者均实现血清转化,但所需疫苗接种次数多于健康个体。
  • 在当前关注变异株中观察到高抗体交叉反应,且发生在Omicron亚变异株适应性加强接种之前。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Faustini SE, Hall A, Brown S, et al. Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. Br J Haematol. 2023. PMID: 36895158. doi:10.1111/bjh.18714

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。